Copyright: ©Author(s) 2026.
World J Gastrointest Oncol. Apr 15, 2026; 18(4): 114567
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.114567
Published online Apr 15, 2026. doi: 10.4251/wjgo.v18.i4.114567
Figure 5 Inhibitors and monoclonal antibodies targeting the cellular-mesenchymal epithelial transition factor/hepatocyte growth factor signaling pathway.
HGF: Hepatocyte growth factor; TAK: Transforming growth factor-β-activated kinase; CT: Computed tomography; ABT-700: Aminobenzotriazole-700; SEMA: Semaglutide; PSI: Patient-specific instrument; PI3K: Phosphoinositide 3-kinase; STAT3: Signal transducer and activator of transcription 3; RAS: Rat sarcoma.
- Citation: Wen JK, Xia J, Yu L, Xu GL, Ye GF, Lin YH. Could deciphering cellular-mesenchymal epithelial transition factor/hepatocyte growth factor network dynamics unlock novel biomarker-driven therapies for colorectal cancer? World J Gastrointest Oncol 2026; 18(4): 114567
- URL: https://www.wjgnet.com/1948-5204/full/v18/i4/114567.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v18.i4.114567